Close

Arrowhead Pharmaceuticals Corp (ARWR) Reports Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease

October 23, 2017 8:07 AM EDT Send to a Friend
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented data from studies demonstrating promising preclinical safety and efficacy of ARO-AAT, a second-generation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login